-
Journal of Cancer Research and Clinical... Jan 2023Meningioma is a common type of benign tumor that can be managed in several ways, ranging from close observation, surgical resection, and various types of radiation. We... (Review)
Review
PURPOSE
Meningioma is a common type of benign tumor that can be managed in several ways, ranging from close observation, surgical resection, and various types of radiation. We present here results from a 10 year experience treating meningiomas with a hypofractionated approach.
MATERIALS AND METHODS
To define the rate of tumor control and factors associated with the relief of symptoms and radiation-related complications after radiosurgery and hypofractionated radiosurgery for patients with imaging-defined intracranial meningiomas. We reviewed the charts of 48 patients treated with stereotactic radiosurgery (SRS) or hypofractionated stereotactic radiotherapy (SRT) from 2002 to 2018. A total of 37 (82%) patients had WHO Grade 1 disease, and 11 (22%) had Grade 2. Outcomes that were analyzed included local control rates and the rate and grade of any reported toxicity.
RESULTS
Only 36 patients with 38 lesions, who underwent the follow-up regime, were enrolled in the retrospective analysis. The follow-up mean was 40 months (12-120 months). 25/34 patients had surgery before the radiotherapy. Sixteen underwent SRS with a median dose of 13, 5, and 20 received hypofractionated SBRT with a median dose of 26.9 (22-45 Gy) in median six fractions (5-13 fractions). Local control at 2 and 5 years for all patients was 90 and 70%, respectively. No patient suffered from toxicity > 2 CTC. 21/36 patients showed stable disease, while 8/36 patients showed partial Remission. 7/36 developed recurrent meningioma (five in-field), only one patient with grade 1 meningioma, in a median of 22 months (13-48 months).
CONCLUSION
SFRT was superior to SRS for local control in our analysis of Grade I meningiomas. This might be due to a tendency for higher EQD2 in the PTV with SFRT compared to SRS, which was reduced to avoid brain necrosis in large PTVs. Therefore, SFRT appears preferable for typical meningioma PTVs.
Topics: Humans; Meningioma; Radiosurgery; Meningeal Neoplasms; Retrospective Studies; Radiation Dose Hypofractionation; Follow-Up Studies; Neoplasm Recurrence, Local; Particle Accelerators; Treatment Outcome
PubMed: 36307558
DOI: 10.1007/s00432-022-04450-y -
European Journal of Nuclear Medicine... Dec 2023Tumor resection represents the first-line treatment for symptomatic meningiomas, and the extent of resection has been shown to be of prognostic importance. Assessment of...
PURPOSE
Tumor resection represents the first-line treatment for symptomatic meningiomas, and the extent of resection has been shown to be of prognostic importance. Assessment of tumor remnants with somatostatin receptor PET proves to be superior to intraoperative estimation with Simpson grading or MRI. In this preliminary study, we evaluate the prognostic relevance of postoperative PET for progression-free survival in meningiomas.
METHODS
We conducted a post hoc analysis on a prospective patient cohort with resected meningioma WHO grade 1. Patients received postoperative MRI and [Ga]Ga-DOTA-TATE PET/CT and were followed regularly with MRI surveillance scans for detection of tumor recurrence/progression.
RESULTS
We included 46 patients with 49 tumors. The mean age at diagnosis was 57.8 ± 1.7 years with a male-to-female ratio of 1:1.7. Local tumor progression occurred in 7/49 patients (14%) after a median follow-up of 52 months. Positive PET was associated with an increased risk for progression (*p = 0.015) and a lower progression-free survival (*p = 0.029), whereas MRI was not. 20 out of 20 patients (100%) with negative PET findings remained recurrence-free. The location of recurrence/progression on MRI was adjacent to regions where postoperative PET indicated tumor remnants in all cases. Gross tumor volumes were higher on PET compared to MRI (*p = 0.032).
CONCLUSION
Our data show that [Ga]Ga-DOTA-TATE PET/CT is highly sensitive in revealing tumor remnants in patients with meningioma WHO grade 1. Negative PET findings were associated with a higher progression-free survival, thus improving surveillance. In patients with tumor remnants, additional PET can optimize adjuvant radiotherapy target planning of surgically resected meningiomas.
Topics: Humans; Male; Female; Middle Aged; Positron Emission Tomography Computed Tomography; Meningioma; Prognosis; Gallium Radioisotopes; Progression-Free Survival; Prospective Studies; Neoplasm Recurrence, Local; Meningeal Neoplasms; World Health Organization; Retrospective Studies; Organometallic Compounds
PubMed: 37642702
DOI: 10.1007/s00259-023-06400-3 -
Journal of Veterinary Diagnostic... Jul 2022Doublecortin (DCX) and neuronal nuclear protein (NeuN) can be used as immunomarkers of neuronal progenitor cells and mature neurons, respectively. Increased DCX...
Doublecortin (DCX) and neuronal nuclear protein (NeuN) can be used as immunomarkers of neuronal progenitor cells and mature neurons, respectively. Increased DCX immunolabeling has been associated with tumor invasion in human gliomas and anaplastic canine meningiomas. These immunomarkers have not been assessed in feline gliomas. Here we characterized the DCX and NeuN immunohistochemistry (IHC) profile in 11 feline gliomas (7 oligodendrogliomas, 4 astrocytomas). Immunolabeling was classified according to intensity (weak, moderate, strong), distribution of neoplastic cell immunolabeling (1 = <30%, 2 = 30-70%, 3 = >70%), and predominant location within the neoplasm (random or at tumor margins). DCX immunolabeling was strong in 6 cases, weak in 4 cases, and moderate in 1 case. The distribution of DCX immunolabeling was characterized as 1 (4 cases), 2 (4 cases), and 3 (3 cases). DCX immunolabeling occurred predominantly in astrocytomas, which had stronger immunostaining at the tumor margins. NeuN immunolabeling was absent in all cases. Our IHC findings are similar to those reported for DCX and NeuN IHC in canine gliomas. The increased DCX immunolabeling at tumor margins is similar to labeling in invasive human gliomas and anaplastic canine meningiomas.
Topics: Animals; Astrocytoma; Brain Neoplasms; Cat Diseases; Cats; Dog Diseases; Dogs; Doublecortin Domain Proteins; Glioma; Meningeal Neoplasms; Meningioma; Microtubule-Associated Proteins; Neurons; Neuropeptides; Nuclear Proteins
PubMed: 35678136
DOI: 10.1177/10406387221104748 -
BMC Cancer May 2022The management of meningiomas is challenging, and the role of postoperative radiotherapy is not standardized.
BACKGROUND
The management of meningiomas is challenging, and the role of postoperative radiotherapy is not standardized.
METHODS
Radiation oncology experts in Swiss centres were asked to participate in this decision-making analysis on the use of postoperative radiotherapy (RT) for meningiomas. Experts from ten Swiss centres agreed to participate and provided their treatment algorithms. Their input was converted into decision trees based on the objective consensus methodology. The decision trees were used as a basis to identify consensus and discrepancies in clinical routine.
RESULTS
Several criteria used for decision-making in postoperative RT in meningiomas were identified: histological grading, resection status, recurrence, location of the tumour, zugzwang (therapeutic need to treat and/or severity of symptoms), size, and cell division rate. Postoperative RT is recommended by all experts for WHO grade III tumours as well as for incompletely resected WHO grade II tumours. While most centres do not recommend adjuvant irradiation for WHO grade I meningiomas, some offer this treatment in recurrent situations or routinely for symptomatic tumours in critical locations. The recommendations for postoperative RT for recurrent or incompletely resected WHO grade I and II meningiomas were surprisingly heterogeneous.
CONCLUSIONS
Due to limited evidence on the utility of postoperative RT for meningiomas, treatment strategies vary considerably among clinical experts depending on the clinical setting, even in a small country like Switzerland. Clear majorities were identified for postoperative RT in WHO grade III meningiomas and against RT for hemispheric grade I meningiomas outside critical locations. The limited data and variations in clinical recommendations are in contrast with the high prevalence of meningiomas, especially in elderly individuals.
Topics: Aged; Child; Humans; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Retrospective Studies; Switzerland
PubMed: 35509011
DOI: 10.1186/s12885-022-09607-z -
In Vivo (Athens, Greece) 2021Lipomatous meningioma (LM) is a form of metaplasia, originating from intracellular lipid bodies accumulation due to metabolic alterations. A comprehensive literature... (Review)
Review
Lipomatous meningioma (LM) is a form of metaplasia, originating from intracellular lipid bodies accumulation due to metabolic alterations. A comprehensive literature review was performed introducing further elements of evaluation. The parameters utilized were age, sex, location, clinical presentation, imaging features, treatment, and recurrences. Seizure and headache are the primary onsets of symptoms. Further LM clinical features, such as visual disturbances and visual epileptic seizures were examined. Symptoms may occur ten years prior to LM finding and it can resolve completely with the indicated surgery. LM computed tomography imaging analysis reveals hypodense regions due to the presence of fat content. On magnetic resonance imaging, the lesion displays hyperintense signal in T1-T2 with signal loss in the fat-suppression sequences. Immunohistochemically, lipidized meningioma cells are positive for Epithelial-Membrane Antigen, Vimentin, CD99, S-100 protein, and progesterone receptor. The recurrence risk rate of LM is estimated to be around 17%. Precise immune-histological findings have been correlated with imaging features to help with early diagnosis. A defined diagnosis of LM is a crucial factor in the choice of treatment.
Topics: Humans; Lipoma; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local; Tomography, X-Ray Computed
PubMed: 34697134
DOI: 10.21873/invivo.12598 -
Neurosurgery Jun 2021
Topics: Cell Proliferation; Humans; Ki-67 Antigen; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local
PubMed: 33826714
DOI: 10.1093/neuros/nyab100 -
International Journal of Molecular... Dec 2022Meningiomas (MGMs) are currently classified into grades I, II, and III. High-grade tumors are correlated with decreased survival rates and increased recurrence rates....
Meningiomas (MGMs) are currently classified into grades I, II, and III. High-grade tumors are correlated with decreased survival rates and increased recurrence rates. The current grading classification is based on histological criteria and determined only after surgical tumor sampling. This study aimed to identify plasma metabolic alterations in meningiomas of different grades, which would aid surgeons in predefining the ideal surgical strategy. Plasma samples were collected from 51 patients with meningioma and classified into low-grade (LG) (grade I; n = 43), and high-grade (HG) samples (grade II, n = 5; grade III, n = 3). An untargeted metabolomic approach was used to analyze plasma metabolites. Statistical analyses were performed to select differential biomarkers among HG and LG groups. Metabolites were identified using tandem mass spectrometry along with database verification. Five and four differential biomarkers were identified for HG and LG meningiomas, respectively. To evaluate the potential of HG MGM metabolites to differentiate between HG and LG tumors, a receiving operating characteristic curve was constructed, which revealed an area under the curve of 95.7%. This indicates that the five HG MGM metabolites represent metabolic alterations that can differentiate between LG and HG meningiomas. These metabolites may indicate tumor grade even before the appearance of histological features.
Topics: Humans; Meningioma; Meningeal Neoplasms; Neoplasm Grading; Retrospective Studies
PubMed: 36613836
DOI: 10.3390/ijms24010394 -
Neuro-oncology Jan 2022
Topics: Humans; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local
PubMed: 34626195
DOI: 10.1093/neuonc/noab225 -
Brain Pathology (Zurich, Switzerland) May 2023Risk prediction for meningioma tumors was until recently almost exclusively based on morphological features of the tumor. To improve risk prediction, multiple models...
Risk prediction for meningioma tumors was until recently almost exclusively based on morphological features of the tumor. To improve risk prediction, multiple models have been established that incorporate morphological and molecular features for an integrated risk prediction score. One such model is the integrated molecular-morphologic meningioma integrated score (IntS), which allocates points to the histological grade, epigenetic methylation family and specific copy-number variations. After publication of the IntS, questions arose in the neuropathological community about the practical and clinical implementation of the IntS, specifically regarding the calling of CNVs, the applicability of the newly available version (v12.5) of the brain tumor classifier and the need for incorporation of TERT-promoter and CDKN2A/B status analysis in the IntS calculation. To investigate and validate these questions additional analyses of the discovery (n = 514), retrospective validation (n = 184) and prospective validation (n = 287) cohorts used for IntS discovery and validation were performed. Our findings suggest that any loss over 5% of the chromosomal arm suffices for the calling of a CNV, that input from the v12.5 classifier is as good or better than the dedicated meningioma classifier (v2.4) and that there is most likely no need for additional testing for TERT-promoter mutations and/or homozygous losses of CDKN2A/B when defining the IntS for an individual patient. The findings from this study help facilitate the clinical implementation of IntS-based risk prediction for meningioma patients.
Topics: Humans; Meningioma; Meningeal Neoplasms; Retrospective Studies; Neoplasm Grading; Epigenomics
PubMed: 36377252
DOI: 10.1111/bpa.13132 -
International Journal of Surgical... Apr 2018We report a case of fibrous meningioma with tyrosine-rich crystalloid in the frontal lobe of a middle-aged woman. The patient presented with a history of several years... (Review)
Review
We report a case of fibrous meningioma with tyrosine-rich crystalloid in the frontal lobe of a middle-aged woman. The patient presented with a history of several years of worsening headaches and blurry vision, which progressed to include syncopal episodes and right-sided weakness. Imaging demonstrated a dural-based extra-axial mass arising from the right orbital roof and extending superiorly along the right frontal convexity causing right-to-left midline shift. The patient underwent a craniotomy and operative resection. Tumor architecture and cytology was similar to that of a Schwannian neoplasm, with spindled cells arranged in a fascicular architecture and displaying focal nuclear palisading. Immunohistochemical stains confirmed a diagnosis of fibrous meningioma. Light microscopy demonstrated extracellular deposits of eosinophilic crystalline material parallel to the spindled tumor cells, reminiscent of "tyrosine-rich" crystals described in salivary gland neoplasms. This is the third meningioma featuring tyrosine-rich crystalloid reported in the literature; we also summarize the previous 2 reports.
Topics: Female; Humans; Meningeal Neoplasms; Meningioma; Middle Aged
PubMed: 28817996
DOI: 10.1177/1066896917727100